Last reviewed · How we verify

NCT06814964

rhTNK-tPA Thrombolytic Removal of Intraventricular Hemorrhage

Recruiting now Phase 1 Last updated 27 February 2025
What this trial tests

Phase 1 trial testing Low dose group in Intraventricular Hemorrhage in 18 participants. Currently enrolling.

Timeline
1 March 2025
Primary endpoint
1 May 2025
1 June 2025

Quick facts

Lead sponsorBeijing Tiantan Hospital
PhasePhase 1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingnone
Primary purposetreatment
Enrollment18
Start date1 March 2025
Primary completion1 May 2025
Estimated completion1 June 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Tiantan Hospital

Who can join

Adults 18 to 80, any sex, with Intraventricular Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this pilot study is to determine the safety and optimal dose of clot lysis with rhTNK-tPA for intraventricular hemorrhage, using stereotactic guidance for extraventricular drain placement.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Low dose group

Trials testing the same drug.

Other recruiting trials for Intraventricular Hemorrhage

Currently open trials in the same condition.

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06814964.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing